FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979464900> ?p ?o ?g. }

• W2979464900 abstract "Abstract Introduction Polatuzumab vedotin (PoV), an antibody-drug-conjugate containing the microtubule inhibitor monomethyl auristatin E (MMAE), is in development for the treatment of B-cell lymphoma (BCL). In phase 1 and 2 studies assessing PoV alone or in combination with rituximab (RTX), PoV treatment until disease progression was associated with high discontinuation rates due to peripheral neuropathy (PN) at the dose of 2.4 mg/kg. Therefore, dose and schedule optimization, including justification of body weight-based dosing, dose capping, and selection of dose level and treatment durations, were evaluated to maximize efficacy and reduce the rate of treatment-emergent PN. Methods Population pharmacokinetics (Pop-PK) for antibody-conjugated MMAE (acMMAE) and exposure-response (E-R) analyses were conducted. A Pop-PK model was developed including clinically relevant covariates recorded in phase 1 and 2 studies of PoV administered every 3 weeks (N=155; Table 1). A simulation was performed to compare acMMAE PK variability with body weight-based vs. fixed dosing. Exposure to acMMAE was also simulated in patients ≥101.9 kg (90th percentile of body weight) receiving a hypothetical capped PoV dose of 240 mg. E-R analyses were stratified by histology, with efficacy based on overall response (OR, complete or partial response per revised IWG criteria [Cheson et al. 2007]) and safety based on the incidence of grade ≥2 PN. Logistic regression and time-to-event analyses were conducted. E-R analyses were also performed to compare safety and efficacy through 8 cycles of treatment vs. treatment discontinuation for disease progression or unacceptable toxicity. Results Pop-PK analysis for acMMAE identified body weight as a significant covariate for both clearance (CLinf) and central volume of distribution (Vc). Simulation suggested that body weight-based dosing (2.4 mg/kg) would result in much lower PK variability than fixed dosing (185.5 mg), with a trend towards slightly higher exposure for patients ≥101.9 kg (Figure 1). This trend of higher exposure was not observed if the PoV dose was capped to 240 mg for these patients. E-R analyses suggested that higher acMMAE exposure was associated with increased likelihood of OR for patients with indolent BCL (including follicular, marginal zone, and small lymphocytic lymphomas; Figure 2) or diffuse large BCL (DLBCL). When acMMAE exposure was translated to the PoV dose, the covariate-adjusted odds ratio (90% confidence interval [CI]) of OR for PoV 2.4 vs. 1.8 mg/kg was 1.73 (1.29-1.74) and 2.39 (1.43-6.13) for indolent BCL and DLBCL, respectively. The effect of adding RTX on PoV efficacy was not statistically significant. Grade ≥2 PN incidence increased with acMMAE exposure for both indolent BCL (Figure 2) and DLBCL. Furthermore, time-to-event analysis indicated that the rate of grade ≥2 PN increased with treatment duration. Based on safety and efficacy through 8 cycles of treatment, the incidence of grade ≥2 PN was decreased, while the higher OR probability for 2.4 mg/kg dose was maintained in both indolent BCL (Figure 2) and DLBCL patients. The time-to-event analysis suggested that treatment with ≤8 cycles of PoV resulted in a model-predicted incidence (90% CI) of grade ≥2 PN events of 28.9% (21.3-34.7%) and 35.1% (26.2-41.7%) for 1.8 and 2.4 mg/kg, respectively. Conclusions Body weight-based dosing for all patients with capping the PoV dose at 240 mg for heavy patients (≥101.9 kg) provides lower PK variability for all patients than fixed dosing and may mitigate potential safety risks for heavy patients. When given alone or in combination with RTX, a PoV dose of 2.4 mg/kg is associated with a higher likelihood of achieving an OR compared with 1.8 mg/kg. Capping treatment to ≤8 cycles may mitigate treatment-emergent PN risk. Thus, selection of PoV dose and/or capping of treatment duration may offer an optimal benefit-risk profile. Current clinical studies are testing PoV 1.8 mg/kg limited to 6-8 cycles to further mitigate safety risk when given in combination with immunochemotherapy or novel small molecule pathway inhibitors. Future clinical testing at the 2.4 mg/kg dose level may also be warranted. Disclosures Lu: Genentech, Inc.: Employment, Equity Ownership. Off Label Use: Polatuzumab vedotin is an investigational agent and not approved in B-cell lymphoma. Jin:Genentech, Inc.: Employment. Gibiansky:Genentech, Inc.: Consultancy. Gillespie:Genentech, Inc.: Consultancy. Agarwal:Genentech, Inc.: Employment. Jones:Genentech, Inc.: Employment. Chu:Genentech, Inc.: Employment. Wenger:Genentech, Inc.: Employment. Hirata:Genentech, Inc.: Employment, Equity Ownership. Li:Genentech, Inc.: Employment. Girish:Genentech, Inc.: Employment." @default.
• W2979464900 created "2019-10-18" @default.
• W2979464900 creator A5011946503 @default.
• W2979464900 creator A5024827460 @default.
• W2979464900 creator A5035445472 @default.
• W2979464900 creator A5040033438 @default.
• W2979464900 creator A5061466414 @default.
• W2979464900 creator A5065578593 @default.
• W2979464900 creator A5074275108 @default.
• W2979464900 creator A5080563975 @default.
• W2979464900 creator A5082723850 @default.
• W2979464900 creator A5085929266 @default.
• W2979464900 creator A5086463590 @default.
• W2979464900 date "2015-12-03" @default.
• W2979464900 modified "2023-09-26" @default.
• W2979464900 title "Exposure-Response Analysis to Assist Selection of Dose and Treatment Duration for Polatuzumab Vedotin As a Single Agent or in Combination with Rituximab for the Treatment of B-Cell Lymphoma" @default.
• W2979464900 doi "https://doi.org/10.1182/blood.v126.23.1525.1525" @default.
• W2979464900 hasPublicationYear "2015" @default.
• W2979464900 type Work @default.
• W2979464900 sameAs 2979464900 @default.
• W2979464900 citedByCount "6" @default.
• W2979464900 countsByYear W29794649002017 @default.
• W2979464900 countsByYear W29794649002019 @default.
• W2979464900 countsByYear W29794649002020 @default.
• W2979464900 crossrefType "journal-article" @default.
• W2979464900 hasAuthorship W2979464900A5011946503 @default.
• W2979464900 hasAuthorship W2979464900A5024827460 @default.
• W2979464900 hasAuthorship W2979464900A5035445472 @default.
• W2979464900 hasAuthorship W2979464900A5040033438 @default.
• W2979464900 hasAuthorship W2979464900A5061466414 @default.
• W2979464900 hasAuthorship W2979464900A5065578593 @default.
• W2979464900 hasAuthorship W2979464900A5074275108 @default.
• W2979464900 hasAuthorship W2979464900A5080563975 @default.
• W2979464900 hasAuthorship W2979464900A5082723850 @default.
• W2979464900 hasAuthorship W2979464900A5085929266 @default.
• W2979464900 hasAuthorship W2979464900A5086463590 @default.
• W2979464900 hasConcept C126322002 @default.
• W2979464900 hasConcept C143998085 @default.
• W2979464900 hasConcept C197934379 @default.
• W2979464900 hasConcept C2777288759 @default.
• W2979464900 hasConcept C2778715236 @default.
• W2979464900 hasConcept C2779338263 @default.
• W2979464900 hasConcept C2780653079 @default.
• W2979464900 hasConcept C2908647359 @default.
• W2979464900 hasConcept C71924100 @default.
• W2979464900 hasConcept C90924648 @default.
• W2979464900 hasConcept C98274493 @default.
• W2979464900 hasConcept C99454951 @default.
• W2979464900 hasConceptScore W2979464900C126322002 @default.
• W2979464900 hasConceptScore W2979464900C143998085 @default.
• W2979464900 hasConceptScore W2979464900C197934379 @default.
• W2979464900 hasConceptScore W2979464900C2777288759 @default.
• W2979464900 hasConceptScore W2979464900C2778715236 @default.
• W2979464900 hasConceptScore W2979464900C2779338263 @default.
• W2979464900 hasConceptScore W2979464900C2780653079 @default.
• W2979464900 hasConceptScore W2979464900C2908647359 @default.
• W2979464900 hasConceptScore W2979464900C71924100 @default.
• W2979464900 hasConceptScore W2979464900C90924648 @default.
• W2979464900 hasConceptScore W2979464900C98274493 @default.
• W2979464900 hasConceptScore W2979464900C99454951 @default.
• W2979464900 hasLocation W29794649001 @default.
• W2979464900 hasOpenAccess W2979464900 @default.
• W2979464900 hasPrimaryLocation W29794649001 @default.
• W2979464900 hasRelatedWork W2127018518 @default.
• W2979464900 hasRelatedWork W2342481353 @default.
• W2979464900 hasRelatedWork W2343867010 @default.
• W2979464900 hasRelatedWork W2376907976 @default.
• W2979464900 hasRelatedWork W2548695469 @default.
• W2979464900 hasRelatedWork W2558885752 @default.
• W2979464900 hasRelatedWork W2561192604 @default.
• W2979464900 hasRelatedWork W2561329745 @default.
• W2979464900 hasRelatedWork W2591855899 @default.
• W2979464900 hasRelatedWork W2922237910 @default.
• W2979464900 hasRelatedWork W2944473604 @default.
• W2979464900 hasRelatedWork W2979332364 @default.
• W2979464900 hasRelatedWork W2979775597 @default.
• W2979464900 hasRelatedWork W2979778744 @default.
• W2979464900 hasRelatedWork W2991103090 @default.
• W2979464900 hasRelatedWork W2994990079 @default.
• W2979464900 hasRelatedWork W2998859020 @default.
• W2979464900 hasRelatedWork W3096478791 @default.
• W2979464900 hasRelatedWork W3097330612 @default.
• W2979464900 hasRelatedWork W3181946323 @default.
• W2979464900 isParatext "false" @default.
• W2979464900 isRetracted "false" @default.
• W2979464900 magId "2979464900" @default.
• W2979464900 workType "article" @default.